Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill could melt fat in people with obesity

NCT ID NCT07169942

Disease control Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new oral drug called aleniglipron (GSBR-1290) in 71 adults with obesity (BMI ≥30). Participants take the drug or a placebo daily for 40 weeks. Researchers measure changes in body fat, waist size, and weight using special scans. The goal is to see if the drug safely reduces fat and improves body composition.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
aleniglipron (GSBR-1290)
What this could lead to
If successful, this could lead to a new oral medication for obesity that reduces body fat and improves body composition.
What could go wrong
This is an early Phase 2 trial with only 71 participants, so results may not apply to everyone. The drug may not work better than placebo or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

71 people

The number who actually took part.

Started

Aug 2025

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 79 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Signed informed consent * Participants age ≥18 years and \<80 years, with BMI ≥30 kg/m2 * Screening HbA1c \<6.5 % Exclusion Criteria: * Previous documented diagnosis of diabetes mellitus * Self-reported change in body weight \>5% within 3 months before Screening * Have a body weight, height, and/or width that prohibits the ability to obtain accurate measurements according to the DXA study specific manual that allows hemi-scan * Have a prior or planned surgical treatment for obesity (excluding liposuction or abdominoplasty, if performed \>1 year prior to screening) * Have obesity induced by other endocrine disorders (such as Cushing's syndrome, Prader-Willi syndrome, or melanocortin 4 receptor deficiency)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity, overweight, or chronic weight management

Contacts and locations

Locations

  • Research Site

    Phoenix, Arizona, 85020, United States

  • Research Site

    Chicago, Illinois, 60602, United States

  • Research Site

    Richfield, Minnesota, 55423, United States

  • Research Site

    City of Saint Peters, Missouri, 63303, United States

  • Research Site

    Rochester, New York, 14609, United States

  • Research Site

    Wilmington, North Carolina, 28401, United States

  • Research Site

    Norman, Oklahoma, 73069, United States

  • Research Site

    Moncks Corner, South Carolina, 29461, United States

  • Research Site

    North Charleston, South Carolina, 29405, United States

  • Research Site

    Austin, Texas, 78704, United States

  • Research Site

    San Antonio, Texas, 78240, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.